Follow-up of the metabolic syndrome induced by atypical antipsychotics: Recommandations and pharmacogenetics perspectives;Suivi du syndrome métabolique induit par les antipsychotiques atypiques: Recommandations et perspectives pharmacogénétiques

Revue Medicale Suisse

Volumn 4, Issue 171, 2008, Pages 1994-1999

  Choong, Eva ^a   Solida, Alessandra ^b   Lechaire, Catherine ^b   Conus, Philippe ^b   Eap, Chin B ^a  

^a Hopital de Cery   (Switzerland)

^b Service de Psychiatrie Générale   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR; AMISULPRIDE; ATYPICAL ANTIPSYCHOTIC AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; CLOZAPINE; CYTOCHROME P450 1A2; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HISTAMINE H1 RECEPTOR; LEPTIN; LEPTIN RECEPTOR; NEUROLEPTIC AGENT; OLANZAPINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; RISPERIDONE; SEROTONIN 2C RECEPTOR; SERTINDOLE; TRIACYLGLYCEROL;

AGRANULOCYTOSIS; CHOLESTEROL BLOOD LEVEL; CONSENSUS DEVELOPMENT; DNA POLYMORPHISM; DRUG EFFICACY; DRUG TOLERANCE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; HYPERPROLACTINEMIA; LIPID BLOOD LEVEL; METABOLIC SYNDROME X; PATIENT COMPLIANCE; PATIENT MONITORING; PHARMACOGENETICS; PRACTICE GUIDELINE; PSYCHOSIS; QT PROLONGATION; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; GLUCOSE INTOLERANCE; HUMANS; LEPTIN; METABOLIC SYNDROME X; PHARMACOGENETICS; RECEPTORS, LEPTIN; WEIGHT GAIN;

EID: 54749115564     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Lehman AF, Lieberman JA, Dixon LB, et al. Practice guidelines for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004;161:1-56.
2. ** American Diabetes Association. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27:596-601.
3. ** Goff DC, Cather C, Evins AE, et al. Medical morbidity and mortality in schizophrenia: Guidelines for psychiatrists. J Clin Psychiatry 2005;66:183-94.
4. Meyer JM, Davis VG, Goff DC, et al. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE schizophrenia trial: Prospective data from phase I. Schizophr Res 2008;101:273-86.
5. Osby U, Correia N, Brandt L. Mortality and causes of death in schizophrenia on Stockholm country, Sweden. Schizophr Res 2000;45:21-8.
6. Casey DE, Hansen. Excessive mortality and morbidity in schizophrenia. In: Meyer JM, Nasrallah HA, editors. Medical illness and schizophrenia. Washington DC: American Psychiatric Publishing, 2003;13-4.
7. Ryan MC, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 2003;160:284-9.
8. ** Heiskanen T, Niskanen L, Lyytikainen R, et al. Metabolic syndrome in patients with schizophrenia. J. Clin Psychiatry 2003;63:575-9.
9. Casey DE. Metabolic issues and cardiovascular disease in patients with psychiatric disorders. Am J Med 2005;118(Suppl.2):15S-22S.
10. Haupt DW. Differential metabolic effects of antipsychotic treatments. Eur Neuropsychopharmacol 2006;16(Suppl.3):S149-S55.
11. Wirshing DA, Schizophrenia and obesity: Impact of antipsychotic medications. J Clin Psychiatry 2004;65(Suppl. 18):13-26.
12. Newcomer JW. Metabolic considerations in the use of antipsychotic medications: A review of recent evidence. J Clin Psychiatry 2007;68(Suppl. 1):20-7.
13. Third report of the National cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult treatment panel III). Final report. Circulation 2002;106:3143-421.
14. Wajchenberg BL. Subcutaneous and visceral adipose tissue: Their relation to the metabolic syndrome. Endocr Rev 2000;21:697-738.
15. * Baumann P, Hiemke C, Ulrich S, et al. Therapeutic monitoring of psychotropic drugs - An outline of the AGNP-TDM expert group consensus guideline. Ther Drug Monit 2004;26:167-70.
16. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487-97.
17. Melkersson KI, Scordo MG, Gunes A, Dahl ML. Impact of CYP1A2 and CYP2D6 polymorphisms on drug metabolism and on insulin and lipid elevations and insulin resistance in clozapine-treated patients. J Clin Psychiatry 2007;68:697-704.
18. Baptista T. Body weight gain induced by antipsychotic drugs: Mechanisms and management (review). Acta Psychiatr Scand 1999;100:3-16.
19. Taylor DM, McAskill R. Atypical antipsychotics and weight gain - a systematic review. Acta Psychiatr Scand 2000;101:416-32.
20. ** Chagnon YC. Susceptibility genes for the side effect of antipsychotics on body weight and obesity. Current Drug Targets 2006;7:1681-95.
21. Zimmermann U, Kraus T, Himmerich H, Schuld A, Pollmächer T. Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients. J Psychiatr Res 2003;37:193-220.
22. Reynolds GP, Zhang ZJ, Zhang XB. Polymorphism of the promoter region of the serotonin 5-HT2C receptor gene and clozapine-induced weight gain. Am J Psychiatry 2003;160:677-9.
23. Ryu S, Cho EY, Park T, et al. -759 C/T polymorphism of 5-HT2C receptor gene and early phase weight gain associated with antipsychotic drug treatment. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:673-7.
24. Templeman LA, Reynolds GP, Arranz B, San L. Polymorphism of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. Pharmacogenetics and Genomics 2005;15:195-200.
25. Mulder H, Franke B, van der-Beek van der AA, et al. The association between HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia. J Clin Psychopharmacol 2007;27:338-43.
26. Kroeze WK, Hufeisen SJ, Popadak BA, et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 2003;28:519-26.
27. Lima JJ, Feng H, Duckworth L, et al. Association analyses of adrenergic receptor polymorphisms with obesity and metabolic alterations. Metabolism 2007;56:757-65.
28. Müller DJ, Klempan TA, De Luca V, et al. The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia. Neurosci Lett 2005;379:81-9.
29. Yasuda K, Matsunaga T, Adachi T, et al. Adrenergic receptor polymorphisms and autonomic nervous system function in human obesity. Trends Endocrinol Metab 2006;17:269-75.
30. Liu Y, Yuan Z, Liu Y, et al. PPARgamma gene C161T substitution is associated with reduced risk of coronary artery disease and decreased proinflammatory cytokine expression. Am Heart J 2007;154:718-24.
31. Ellingrod VL, Bishop JR, Moline J, et al. Leptin and leptin receptor gene polymorphisms and increases in body mass index (BMI) from olanzapine treatment in persons with schizophrenia. Psychopharmacol Bull 2007;40:57-62.
32. Yevtushenko OO, Cooper SJ, O'Neill R, et al. Influence of 5-HT2C receptor and leptin gene polymorphisms, smoking and drug treatment on metabolic disturbances in patients with schizophrenia. Br J Psychiatry 2008;192:424-8.
33. Zhang XY, Zhou DF, Wu GY, et al. BDNF Levels and genotype are associated with antipsychotic-induced weight gain in patients with chronic schizophrenia. Neuropsychopharmacology 2008;33:2200-5.